Literature DB >> 7525988

Exploration of antigenic variation in gp120 from clades A through F of human immunodeficiency virus type 1 by using monoclonal antibodies.

J P Moore1, F E McCutchan, S W Poon, J Mascola, J Liu, Y Cao, D D Ho.   

Abstract

The reactivities of a panel of 14 monoclonal antibodies (MAbs) with monomeric gp120 derived from 67 isolates of human immunodeficiency virus type 1 of clades A through F were assessed by using an antigen-capture enzyme-linked immunosorbent assay. The MAbs used were all raised against gp120 or gp120 peptides from clade B viruses and were directed at a range of epitopes relevant to human immunodeficiency virus type 1 neutralization: the V2 and V3 loops, discontinuous epitopes overlapping the CD4-binding site, and two other discontinuous epitopes. Four of the five V3 MAbs showed modest cross-reactivity within clade B but very limited reactivity with gp120s from other clades. These reactivity patterns are consistent with the known primary sequence requirements for the binding of these MAbs. One V3 human MAb (19b), however, was much more broadly reactive than the others, binding to 19 of 29 clade B and 10 of 12 clade E gp120s. The 19b epitope is confined to the flanks of the V3 loop, and these sequences are relatively conserved in clade B and E viruses. In contrast to the limited reactivity of V3 MAbs, CD4-binding site MAbs were much more broadly reactive across clades, two of these MAbs (205-46-9 and 21h) being virtually pan-reactive across clades A through F. Another human MAb (A-32) to a discontinuous epitope was also pan-reactive. The CD4-binding site is strongly conserved between clades; but when considering the epitopes near the CD4-binding site, clade D gp120 appears to be the most closely related to clade B and clade E appears to be the least related. A tentative rank order for these epitopes is B/D-A/C-E/F. V2 MAbs reacted sporadically within and between clades, and no clear pattern was observable. While results from binding assays do not predict neutralization serotypes, they suggest that there may be antigenic subtypes related, but not identical, to the genetic subtypes.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7525988      PMCID: PMC237304     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  73 in total

1.  Immunochemical analysis of the gp120 surface glycoprotein of human immunodeficiency virus type 1: probing the structure of the C4 and V4 domains and the interaction of the C4 domain with the V3 loop.

Authors:  J P Moore; M Thali; B A Jameson; F Vignaux; G K Lewis; S W Poon; M Charles; M S Fung; B Sun; P J Durda
Journal:  J Virol       Date:  1993-08       Impact factor: 5.103

2.  Broadly neutralizing monoclonal antibodies to the V3 region of HIV-1 can be elicited by peptide immunization.

Authors:  M E White-Scharf; B J Potts; L M Smith; K A Sokolowski; J R Rusche; S Silver
Journal:  Virology       Date:  1993-01       Impact factor: 3.616

3.  Major glycoprotein antigens that induce antibodies in AIDS patients are encoded by HTLV-III.

Authors:  J S Allan; J E Coligan; F Barin; M F McLane; J G Sodroski; C A Rosen; W A Haseltine; T H Lee; M Essex
Journal:  Science       Date:  1985-05-31       Impact factor: 47.728

4.  Covariation of mutations in the V3 loop of human immunodeficiency virus type 1 envelope protein: an information theoretic analysis.

Authors:  B T Korber; R M Farber; D H Wolpert; A S Lapedes
Journal:  Proc Natl Acad Sci U S A       Date:  1993-08-01       Impact factor: 11.205

5.  Characterization of envelope and core structural gene products of HTLV-III with sera from AIDS patients.

Authors:  W G Robey; B Safai; S Oroszlan; L O Arthur; M A Gonda; R C Gallo; P J Fischinger
Journal:  Science       Date:  1985-05-03       Impact factor: 47.728

6.  Genomic cloning and complete sequence analysis of a highly divergent African human immunodeficiency virus isolate.

Authors:  M Vanden Haesevelde; J L Decourt; R J De Leys; B Vanderborght; G van der Groen; H van Heuverswijn; E Saman
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

7.  Identification of human immunodeficiency virus type 1 subtypes and their distribution in the Commonwealth of Independent States (Former Soviet Union) by serologic V3 peptide-binding assays and V3 sequence analysis.

Authors:  R Cheingsong-Popov; A Bobkov; M M Garaev; P Kaleebu; D Callow; A Rzhiminova; S R Saukhat; N P Burdajev; N D Kolomijets; J N Weber
Journal:  J Infect Dis       Date:  1993-08       Impact factor: 5.226

8.  V3 loop of the human immunodeficiency virus type 1 Env protein: interpreting sequence variability.

Authors:  L Milich; B Margolin; R Swanstrom
Journal:  J Virol       Date:  1993-09       Impact factor: 5.103

9.  Molecular epidemiology of HIV-1 based on phylogenetic analysis of in vivo gag p7/p9 direct sequences.

Authors:  M Salminen; A Nykänen; H Brummer-Korvenkontio; M L Kantanen; K Liitsola; P Leinikki
Journal:  Virology       Date:  1993-07       Impact factor: 3.616

10.  Evidence for the cooperation of gp120 amino acids 322 and 448 in SIVmac entry.

Authors:  H G Morrison; F Kirchhoff; R C Desrosiers
Journal:  Virology       Date:  1993-07       Impact factor: 3.616

View more
  78 in total

Review 1.  Genetic subtypes, humoral immunity, and human immunodeficiency virus type 1 vaccine development.

Authors:  J P Moore; P W Parren; D R Burton
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

2.  Hyperglycosylated mutants of human immunodeficiency virus (HIV) type 1 monomeric gp120 as novel antigens for HIV vaccine design.

Authors:  Ralph Pantophlet; Ian A Wilson; Dennis R Burton
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

3.  Association of structural changes in the V2 and V3 loops of the gp120 envelope glycoprotein with acquisition of neutralization resistance in a simian-human immunodeficiency virus passaged in vivo.

Authors:  Y Ye; Z H Si; J P Moore; J Sodroski
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

4.  Mutagenic stabilization and/or disruption of a CD4-bound state reveals distinct conformations of the human immunodeficiency virus type 1 gp120 envelope glycoprotein.

Authors:  Shi-Hua Xiang; Peter D Kwong; Rishi Gupta; Carlo D Rizzuto; David J Casper; Richard Wyatt; Liping Wang; Wayne A Hendrickson; Michael L Doyle; Joseph Sodroski
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

5.  Detection of HIV gp120 in plasma during early HIV infection is associated with increased proinflammatory and immunoregulatory cytokines.

Authors:  Jenna Rychert; Daryld Strick; Sue Bazner; James Robinson; Eric Rosenberg
Journal:  AIDS Res Hum Retroviruses       Date:  2010-08-19       Impact factor: 2.205

6.  Sequential CD4-coreceptor interactions in human immunodeficiency virus type 1 Env function: soluble CD4 activates Env for coreceptor-dependent fusion and reveals blocking activities of antibodies against cryptic conserved epitopes on gp120.

Authors:  K Salzwedel; E D Smith; B Dey; E A Berger
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

7.  Identification of amino acid substitutions associated with neutralization phenotype in the human immunodeficiency virus type-1 subtype C gp120.

Authors:  Jennifer L Kirchherr; Jennifer Hamilton; Xiaozhi Lu; S Gnanakaran; Mark Muldoon; Marcus Daniels; Webster Kasongo; Victor Chalwe; Chanda Mulenga; Lawrence Mwananyanda; Rosemary M Musonda; Xing Yuan; David C Montefiori; Bette T Korber; Barton F Haynes; Feng Gao
Journal:  Virology       Date:  2010-10-30       Impact factor: 3.616

8.  Cross-clade human immunodeficiency virus (HIV)-specific cytotoxic T-lymphocyte responses in HIV-infected Zambians.

Authors:  M R Betts; J Krowka; C Santamaria; K Balsamo; F Gao; G Mulundu; C Luo; N N'Gandu; H Sheppard; B H Hahn; S Allen; J A Frelinger
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

9.  Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG.

Authors:  A Trkola; A B Pomales; H Yuan; B Korber; P J Maddon; G P Allaway; H Katinger; C F Barbas; D R Burton; D D Ho
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

10.  Antigenic properties of the human immunodeficiency virus envelope during cell-cell fusion.

Authors:  C M Finnegan; W Berg; G K Lewis; A L DeVico
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.